Strategies to overcome such immune resistance are underway, including the modification of tumor vasculature by targeting endothelial growth factor receptor (EGFR) or vascular endothelial growth factor receptor (VEGFR), combination with the lymphocyte activation gene-3 (LAG3) inhibitor as well as enhancing the tumor-specific T cells with personalized approaches such as CAR T cell therapy [29–31]. This evidence concerns the gene EGFR and neoplasm.